Literature DB >> 16754373

Optimization of the entrapment of bacterial cell envelope extracts into microparticles for vaccine delivery.

Maite Estevan1, Carlos Gamazo, Gustavo González-Gaitano, Juan M Irache.   

Abstract

The encapsulation of a Brucella ovis extract (HS) in microparticles has been proved effective against experimental infections in mice. This work describes different strategies to increase the HS loading and prepare large batches as necessary to test this vaccine in ovine. The mixture of HS with beta-cyclodextrin was optimized in order to increase the HS loading in microparticles. On the other hand, TROMS ('Total Recirculation One-Machine System') led microparticles with a more homogeneous size than the laboratory or standard procedure. Moreover, the initial burst release of HS from the standard microparticles was higher than for the TROMS ones. In fact, standard microparticles displayed a higher amount of adsorbed HS. On the contrary, both preparative methods were found effective to preserve the integrity and anti-genicity of the loaded HS. In summary, beta-CD can be used to increase the loading of large hydrophobic materials and TROMS is a valid large production of antigen-loaded microparticles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16754373     DOI: 10.1080/02652040500435253

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  2 in total

1.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

2.  The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.

Authors:  A M Arenas-Gamboa; T A Ficht; M M Kahl-McDonagh; G Gomez; A C Rice-Ficht
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.